Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalNo recent work listed

Yuto Yamada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8065-9037; OpenAlex author ID A5006194724. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2020: 1 paper · 2021: 8 papers · 2022: 5 papers · 2023: 2 papers

Papers 16

  1. The efficacy and safety of a duckbill-type anti-reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreat… Co-author DOI 10.1002/deo2.205↗
  2. Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysf… Co-author DOI 10.1007/s00464-022-09836-0↗
  3. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Co-author DOI 10.1016/j.pan.2022.04.003↗
  4. Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.0492-22↗
  5. Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8848-21↗
  6. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/invivo.13024↗
  7. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. Co-author DOI 10.3390/ijms23031205↗
  8. Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. Co-author DOI 10.1007/s10147-020-01827-2↗
  9. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-021-01912-0↗
  10. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-021-01480-w↗
  11. Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Co-author DOI 10.1016/j.pan.2021.03.006↗
  12. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyaa247↗
  13. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyab014↗
  14. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyab091↗
  15. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancre… Co-author DOI 10.1097/mpa.0000000000001801↗
  16. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. Co-author DOI 10.1186/s12885-020-06945-8↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takashi Sasaki · 16 shared papers, 2020–2023 · strength 2.14
  2. Tsuyoshi Takeda · 16 shared papers, 2020–2023 · strength 2.14
  3. Akiyoshi Kasuga · 16 shared papers, 2020–2023 · strength 2.14
  4. Masato Ozaka · 16 shared papers, 2020–2023 · strength 2.14
  5. Takafumi Mie · 16 shared papers, 2020–2023 · strength 2.14
  6. Takaaki Furukawa · 16 shared papers, 2020–2023 · strength 2.14
  7. Masato Matsuyama · 16 shared papers, 2020–2023 · strength 2.14
  8. Naoki Sasahira · 16 shared papers, 2020–2023 · strength 2.14
  9. Takeshi Okamoto · 9 shared papers, 2021–2023 · strength 1.26
  10. Yu Takahashi · 3 shared papers, 2021–2022 · strength 0.38
  11. Manabu Takamatsu · 2 shared papers, 2021–2022 · strength 0.25
  12. Yosuke Inoue · 1 shared paper, 2022 · strength 0.13
  13. Akio Saiura · 1 shared paper, 2022 · strength 0.13
  14. Yuta Ushida · 1 shared paper, 2022 · strength 0.13
  15. Hiroki Nakagawa · 1 shared paper, 2022 · strength 0.13
  16. Yoshihiro Ono · 1 shared paper, 2021 · strength 0.11
  17. Masashi Sawada · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.